CoQ10 for Fatty Liver: What the Evidence Shows

CoQ10 (coenzyme Q10) is increasingly discussed as a potential supplement for fatty liver disease, but understanding what the evidence actually shows is essential before considering it. Fatty liver disease, particularly metabolic dysfunction-associated steatotic liver disease (MASLD), affects a significant proportion of UK adults and carries serious long-term risks if left unmanaged. This article examines how CoQ10 works, what current research says about its effects on liver health, its safety profile, and whether it offers any meaningful advantage over established, evidence-based treatments recommended by NICE and UK clinical bodies.

What is fatty liver disease and why does it develop?

Fatty liver disease occurs when excess fat accumulates in liver cells, impairing function. MASLD, the most common form in the UK, is closely linked to obesity, type 2 diabetes, insulin resistance, and poor diet.

Fatty liver disease is a condition in which excess fat accumulates within liver cells, impairing normal liver function over time. It is broadly divided into two main types: alcohol-related fatty liver disease (ARLD), caused by heavy or prolonged alcohol use, and metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD). MASLD is now the preferred term used by UK clinical bodies, reflecting its close links to metabolic risk factors.^[1][3]

The condition develops when the liver processes more fat than it can efficiently export or break down. Key contributing factors include:

• Obesity and excess visceral fat

• Type 2 diabetes and insulin resistance

• High triglyceride or cholesterol levels

• A diet high in refined carbohydrates and ultra-processed foods

• Physical inactivity

MASLD is one of the most common liver conditions in the UK, affecting a substantial proportion of adults, particularly those with obesity or type 2 diabetes, according to the British Liver Trust. In many people it causes no symptoms in its early stages, but without intervention it can progress through stages of increasing inflammation (steatohepatitis), fibrosis, and, in a minority of cases, cirrhosis or liver failure. It is worth noting that liver function tests (LFTs) may be normal even in people with established MASLD.

NICE guidance (NG49) sets out a risk-stratified approach to identifying and managing MASLD. For people with suspected MASLD or abnormal liver tests, a first-line non-invasive fibrosis score such as the FIB-4 or NAFLD Fibrosis Score (NFS) is used to guide further investigation. Those at intermediate or high risk may be referred for second-line assessment such as the Enhanced Liver Fibrosis (ELF) test or transient elastography (FibroScan).^[1][2] Referral to hepatology is recommended where advanced fibrosis is suspected.

If you experience any of the following, seek urgent medical assessment: jaundice (yellowing of the skin or eyes), abdominal swelling (ascites), vomiting blood or passing black tarry stools, confusion or excessive drowsiness, or severe pain in the upper right abdomen with fever. These may indicate advanced liver disease or a serious complication requiring prompt review.

Understanding what supplements such as CoQ10 may or may not offer requires this clinical context as a starting point.

How does CoQ10 work in the body?

CoQ10 supports mitochondrial ATP production and acts as a lipid-soluble antioxidant, neutralising free radicals. Levels decline with age and may be lower in people with chronic liver disease.

CoQ10 (coenzyme Q10, also called ubiquinone) is a fat-soluble compound produced naturally by the body and found in small amounts in foods such as oily fish, organ meats, nuts and whole grains. It plays two central roles in human physiology: energy production and antioxidant defence.

Within cells, CoQ10 is concentrated in the mitochondria, the structures responsible for generating adenosine triphosphate (ATP), the body's primary energy currency. It acts as an electron carrier in the mitochondrial respiratory chain, shuttling electrons between protein complexes to drive ATP synthesis.^[19][20] Organs with high energy demands, including the heart, kidneys and liver, contain particularly high concentrations of CoQ10.

CoQ10 also functions as a lipid-soluble antioxidant. In its reduced form (ubiquinol), it neutralises free radicals and helps regenerate other antioxidants, including vitamin E. This is relevant to liver disease because oxidative stress, the imbalance between free radical production and antioxidant defences, is thought to be a key driver of liver cell injury and inflammation in MASLD.

Natural CoQ10 levels in the body decline with age. Statins inhibit the same metabolic pathway (the mevalonate pathway) used to synthesise CoQ10, and some studies suggest they may reduce circulating CoQ10 levels, though the clinical significance of this remains debated.^[13][14] If you are taking a statin, do not stop or alter your dose without speaking to your GP first, as statins provide important cardiovascular benefits. People with chronic diseases, including liver disease, may have lower circulating CoQ10 levels than healthy individuals, though whether this is a cause or consequence of disease remains an area of ongoing research.

Supplemental CoQ10 is available in two forms, ubiquinone and ubiquinol. Some studies suggest ubiquinol may be more readily absorbed, particularly in older adults, but the evidence on comparative bioavailability is not conclusive and better absorption does not necessarily translate into superior clinical outcomes.

What does the current evidence say about CoQ10 and liver health?

Small trials show CoQ10 may reduce liver enzymes and oxidative stress markers in MASLD, but no human evidence demonstrates improvements in fibrosis or liver tissue, and no UK body recommends it clinically.

CoQ10 shows some promise in early research for supporting liver health, but the evidence base remains limited and is not yet sufficient to support a clinical recommendation. Several small randomised controlled trials have examined CoQ10 supplementation in people with MASLD, with some reporting improvements in liver enzyme levels (particularly ALT and AST), markers of oxidative stress, and measures of insulin resistance. A 2019 meta-analysis published in Complementary Therapies in Medicine found that CoQ10 supplementation was associated with reductions in liver enzymes and inflammatory markers in people with MASLD, though the authors noted that the included trials were small, short in duration, and heterogeneous in design.

Importantly, the human studies conducted to date have relied on surrogate markers such as ALT, AST and HOMA-IR rather than clinically meaningful endpoints such as liver histology or fibrosis stage. There is currently no evidence from human trials that CoQ10 supplementation reduces liver fibrosis or produces meaningful improvements in liver tissue.

The proposed mechanisms are biologically plausible. Because MASLD involves mitochondrial dysfunction and elevated oxidative stress within liver cells, a compound that supports mitochondrial energy production and reduces free radical damage could theoretically slow disease progression. Animal studies have shown CoQ10 can reduce hepatic fat accumulation and inflammation, but translating these findings to humans requires larger, longer-term trials.

No major UK clinical body, including NICE (NG49), the British Society of Gastroenterology, or the British Liver Trust, currently recommends CoQ10 as a treatment for fatty liver disease.^[1][17] The evidence that does exist is preliminary and should not be interpreted as a substitute for established interventions.

For people seeking evidence-based management of MASLD, the current NICE-aligned approach centres on sustained weight loss, regular physical activity, and management of associated metabolic conditions such as type 2 diabetes and dyslipidaemia.

Are there any side effects or risks of taking CoQ10?

CoQ10 is generally well tolerated at 100 to 300 mg per day; the main clinical risk is a potential interaction with warfarin that may reduce INR control, requiring GP advice before use.

CoQ10 is generally considered well tolerated in adults when taken at doses used in clinical trials, which have typically ranged from 100 mg to 300 mg per day.^[8] Because it is a naturally occurring compound, serious adverse effects are uncommon, and no significant toxicity has been identified in human studies at these doses.

The most frequently reported side effects are mild and gastrointestinal in nature, including:

• Nausea or stomach discomfort, particularly when taken on an empty stomach

• Diarrhoea or loose stools

• Reduced appetite

• Headache or dizziness in some individuals

Taking CoQ10 with food, especially a meal containing some fat, can improve both tolerability and absorption, as it is a fat-soluble compound.

A clinically important consideration is CoQ10's potential interaction with anticoagulant medicines, particularly warfarin. Some evidence suggests CoQ10 may reduce the anticoagulant effect of warfarin, potentially affecting INR control.^[9][10] Anyone taking warfarin or other blood-thinning medicines should speak to their GP or anticoagulation clinic before starting CoQ10, and closer INR monitoring may be appropriate when starting or stopping the supplement.

CoQ10 may also have a mild blood-pressure-lowering effect, which could be relevant for people already taking antihypertensive medicines. Some studies have reported modest reductions in blood glucose; people with diabetes should be aware of this and discuss it with their GP or diabetes team, as it does not replace prescribed diabetes treatment.

CoQ10 is not recommended during pregnancy or breastfeeding due to insufficient safety data. If you are pregnant, planning a pregnancy, or breastfeeding, speak to your GP or midwife before taking any supplement.

CoQ10 is classified as a food supplement in the UK and is regulated under food law by the Food Standards Agency (FSA) and the Office for Product Safety and Standards (OPSS), with enforcement by local authorities.^[16] It is not regulated as a medicine by the MHRA, and quality and dose accuracy can vary between products. If you experience any unexpected symptoms after starting CoQ10, contact your GP. Suspected adverse reactions to supplements can be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Should you take CoQ10 for fatty liver, or are there better options?

Lifestyle modification, including 7 to 10 per cent weight loss, regular exercise, and dietary improvement, has the strongest evidence for MASLD and should be prioritised over CoQ10 supplementation.

CoQ10 is not a recommended treatment for fatty liver disease, and lifestyle modification remains the most effective and evidence-based approach for most people with MASLD. While the early research on CoQ10 is interesting, it does not yet provide sufficient evidence to justify its use as a primary or adjunct therapy for liver disease outside of a research setting. Choosing a supplement over proven interventions risks delaying meaningful treatment.

The interventions with the strongest evidence base for MASLD include:

• Sustained weight loss of around 7 to 10 per cent of body weight, which NICE (NG49) and international guidelines identify as a target associated with significant reductions in liver fat and inflammation

• Regular aerobic and resistance exercise, which improves insulin sensitivity and reduces hepatic fat independently of weight loss

• Dietary changes, including reducing refined carbohydrates, added sugars and ultra-processed foods, and following a Mediterranean-style dietary pattern

• Optimising management of type 2 diabetes, hypertension and dyslipidaemia, which are closely linked to MASLD progression

For people with type 2 diabetes or obesity and MASLD, certain medicines such as GLP-1 receptor agonists are licensed for the management of type 2 diabetes and weight management respectively. Some clinical trials, including the LEAN trial (liraglutide) and a phase 3 trial of semaglutide in NASH, have reported improvements in liver-related endpoints as secondary or exploratory outcomes.^[7] However, GLP-1 receptor agonists are not currently licensed specifically for MASLD in the UK, and any prescribing decision should follow UK licences and NICE guidance.^[18] Your GP or hepatology team can advise on whether any pharmacological treatment is appropriate for your individual circumstances.

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, which may be relevant for people whose MASLD is linked to excess weight.

If you have been diagnosed with fatty liver disease, or if you have risk factors such as obesity, type 2 diabetes or persistently elevated liver enzymes, speak to your GP rather than self-treating with supplements. Your GP can arrange appropriate investigations, including liver function tests and imaging, calculate a non-invasive fibrosis score (such as FIB-4 or NFS), and refer you to a specialist if needed.

Scientific References

1. Metabolic dysfunction-associated steatotic liver disease (NG49).
2. Metabolic dysfunction-associated steatotic liver disease – recommendations for research (NG49).
3. Scope for guideline update (GID-NG10434).
4. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
5. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
6. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis.
7. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN trial).
8. Functions of Coenzyme Q10 Supplementation on Liver Enzymes, Markers of Systemic Inflammation, and Adipokines in Patients Affected by Nonalcoholic Fatty Liver Disease.
9. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial.
10. [Interaction between warfarin and coenzyme Q10].
11. Risk of warfarin-related bleeding events and supratherapeutic INRs associated with complementary and alternative medicine.
12. [Effect of Coenzyme Q10 and Ginkgo biloba on warfarin dosage – randomised, double-blind, placebo-controlled cross-over trial].
13. Coenzyme Q10 and statin myalgia: what is the evidence?.
14. Exogenous CoQ10 preserves plasma ubiquinone levels in patients treated with HMG-CoA reductase inhibitors.
15. Coenzyme Q10: is there a clinical role and a case for measurement?.
16. Food supplements – guidance for businesses.
17. Non-alcoholic fatty liver disease (NAFLD).
18. Semaglutide (Wegovy) approved to treat form of liver disease.
19. The Drp1-CoQ10-Coa6-ETC axis represents a therapeutic potential for working memory impairment caused by neuronal mitochondrial dysfunction.
20. Coq4 deficiency induces placental vascular development defects through FSP1/CoQ10 axis-mediated endothelial ferroptosis.

Frequently Asked Questions